International Prognostic Scoring System for Mastocytosis (IPSM)
Prognosticates survival outcomes for patients with nonadvanced and advanced systemic mastocytosis.
Advice
- This tool should not be used as the sole basis for care.
- Management of systemic mastocytosis should be guided by a comprehensive clinical evaluation and clinician judgment, regardless of the IPSM score.
- Results may help contextualize WHO classification and aid in treatment discussions.
Management
The validation study did not lead to any specific management recommendations but suggested considering risk stratification when balancing tradeoffs between curative potential and side effects of treatment options.